Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence

BACKGROUND: This study aims to determine if the intravitreal dexamethasone implant (DEX implant, Ozurdex; Allergan, Inc., Irvine, California) is effective for treating intermediate, posterior, and panuveitis as a monotherapy or adjunctive treatment to systemic immunomodulatory therapies. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Saincher, Saanwalshah Samir, Gottlieb, Chloe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954157/
https://www.ncbi.nlm.nih.gov/pubmed/31925591
http://dx.doi.org/10.1186/s12348-019-0189-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954157/
https://www.ncbi.nlm.nih.gov/pubmed/31925591
http://dx.doi.org/10.1186/s12348-019-0189-4

Ejemplares similares